Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 20, Issue 3

May-June 2023

In this Issue

Clinical Trials Corner
Diffusion
Feature
Headlines from Washington
Letter to the Editor
Mini Review
President’s Column

Clinical Trials Corner

Expanding the Repertoire in Myelodysplastic Syndromes: Studying the Sequence of Therapies in Lower-risk Transfusion-dependent Disease

Andrew M. Brunner, MD,Robert P. Hasserjian, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias

Andrew D Hughes, MD PhD,Sarah K Tasian, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Diffusion

Why Are There So Few Drugs to Treat Sickle Cell Disease?

David Rees, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Anticoagulation and Abnormal Uterine Bleeding: Acknowledging Calls to Action

Sumedha Arya, MD,Michael Scott, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Gene Therapy for Germline Predisposition to Myeloid Malignancies: Insights from a Nonhuman Primate RUNX1 Model

Christine M. McMahon, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Understanding the T Cells That Cause GVHD: An Ever-replenishing Pool, or Tissue-specific Reservoirs?

Kate A. Markey, MBBS, MClinRes, PhD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Total Body Irradiation for Myeloablative Allogeneic Hematopoietic Transplantation in Acute Lymphoblastic Leukemia: How Important Is It Really?

Clayton Jackson, MD,Lori Muffly, MD, MS

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

FDA Approval of Gene Therapy for Hemophilia B: The Dawn of a New Era in Hemophilia Care

Surbhi Shah, MBBS, MD,Rajiv K. Pruthi, MBBS

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

In Myelofibrosis, Is It the Megs or the Tregs?

Bethan Psaila, MD, PhD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The Yin and Yang of CAR T-cell Therapy: Lessons to Be Learned from Noninvasive Profiling

Loretta J. Nastoupil, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Smoldering Multiple Myeloma: Data on Prevalence at Last

Malin Hultcrantz, MD, PhD,Saad Z. Usmani, MD, MBA

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Feature

Hematologic Malignancies and the Food and Drug Administration’s Accelerated Approval Program

Patrick Demoss, MD,Bindu Kanapuru, MD,Nicole Gormley, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Headlines from Washington

Nominations Now Open for ASH Members to Become Effective Advocates

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Letter to the Editor

Please Don’t Call Me a Classical Hematologist

Steven R. Lentz, MD, PhD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Mini Review

Not So Benign
Cold Agglutinin Disease: New Direction for an Old Disease

Surbhi Shah, MBBS, MD,Ronald S. Go, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

President’s Column

Hello World! ASH Is Global and Making a Difference

Robert A. Brodsky, MD

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cover Image

All Issues

Advertisement intended for health care professionals

Email alerts

Latest Issue Alert

Continuous Publishing Alert

New Journal Content Alert

Close Modal

Latest
Most Read

Best in Class? DLBclass, a New Classification Tool for Diffuse Large B-Cell Lymphoma to Facilitate Development of Molecular-Based Precision Treatments

Technology Spotlight
New Dimensions for Platelet Evaluation in Hematology Diagnostics

Viscoelastic Testing for Perioperative Bleeding Management

Committee Corner
The ASH Foundation Is a Reflection of the Society

Truly COSMIC: An ASH Research Collaborative First

Advertisement intended for health care professionals

Table of Contents

Clinical Trials Corner

Expanding the Repertoire in Myelodysplastic Syndromes: Studying the Sequence of Therapies in Lower-risk Transfusion-dependent Disease

In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias

Diffusion

Why Are There So Few Drugs to Treat Sickle Cell Disease?

Anticoagulation and Abnormal Uterine Bleeding: Acknowledging Calls to Action

Gene Therapy for Germline Predisposition to Myeloid Malignancies: Insights from a Nonhuman Primate RUNX1 Model

Understanding the T Cells That Cause GVHD: An Ever-replenishing Pool, or Tissue-specific Reservoirs?

Total Body Irradiation for Myeloablative Allogeneic Hematopoietic Transplantation in Acute Lymphoblastic Leukemia: How Important Is It Really?

FDA Approval of Gene Therapy for Hemophilia B: The Dawn of a New Era in Hemophilia Care

In Myelofibrosis, Is It the Megs or the Tregs?

The Yin and Yang of CAR T-cell Therapy: Lessons to Be Learned from Noninvasive Profiling

Smoldering Multiple Myeloma: Data on Prevalence at Last

Feature

Hematologic Malignancies and the Food and Drug Administration’s Accelerated Approval Program

Headlines from Washington

Nominations Now Open for ASH Members to Become Effective Advocates

Letter to the Editor

Please Don’t Call Me a Classical Hematologist

Mini Review

Not So Benign
Cold Agglutinin Disease: New Direction for an Old Disease

President’s Column

Hello World! ASH Is Global and Making a Difference

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Clinical Trials Corner

Expanding the Repertoire in Myelodysplastic Syndromes: Studying the Sequence of Therapies in Lower-risk Transfusion-dependent Disease Free

In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias Free

Diffusion

Why Are There So Few Drugs to Treat Sickle Cell Disease? Free

Anticoagulation and Abnormal Uterine Bleeding: Acknowledging Calls to Action Free

Gene Therapy for Germline Predisposition to Myeloid Malignancies: Insights from a Nonhuman Primate RUNX1 Model Free

Understanding the T Cells That Cause GVHD: An Ever-replenishing Pool, or Tissue-specific Reservoirs? Free

Total Body Irradiation for Myeloablative Allogeneic Hematopoietic Transplantation in Acute Lymphoblastic Leukemia: How Important Is It Really? Free

FDA Approval of Gene Therapy for Hemophilia B: The Dawn of a New Era in Hemophilia Care Free

In Myelofibrosis, Is It the Megs or the Tregs? Free

The Yin and Yang of CAR T-cell Therapy: Lessons to Be Learned from Noninvasive Profiling Free

Smoldering Multiple Myeloma: Data on Prevalence at Last Free

Feature

Hematologic Malignancies and the Food and Drug Administration’s Accelerated Approval Program Free

Headlines from Washington

Nominations Now Open for ASH Members to Become Effective Advocates Free

Letter to the Editor

Please Don’t Call Me a Classical Hematologist Free

Mini Review

Not So BenignCold Agglutinin Disease: New Direction for an Old Disease Free

President’s Column

Hello World! ASH Is Global and Making a Difference Free

Email alerts

ASH Publications

American Society of Hematology

Expanding the Repertoire in Myelodysplastic Syndromes: Studying the Sequence of Therapies in Lower-risk Transfusion-dependent Disease

In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias

Why Are There So Few Drugs to Treat Sickle Cell Disease?

Anticoagulation and Abnormal Uterine Bleeding: Acknowledging Calls to Action

Gene Therapy for Germline Predisposition to Myeloid Malignancies: Insights from a Nonhuman Primate RUNX1 Model

Understanding the T Cells That Cause GVHD: An Ever-replenishing Pool, or Tissue-specific Reservoirs?

Total Body Irradiation for Myeloablative Allogeneic Hematopoietic Transplantation in Acute Lymphoblastic Leukemia: How Important Is It Really?

FDA Approval of Gene Therapy for Hemophilia B: The Dawn of a New Era in Hemophilia Care

In Myelofibrosis, Is It the Megs or the Tregs?

The Yin and Yang of CAR T-cell Therapy: Lessons to Be Learned from Noninvasive Profiling

Smoldering Multiple Myeloma: Data on Prevalence at Last

Hematologic Malignancies and the Food and Drug Administration’s Accelerated Approval Program

Nominations Now Open for ASH Members to Become Effective Advocates

Please Don’t Call Me a Classical Hematologist

Not So Benign
Cold Agglutinin Disease: New Direction for an Old Disease

Hello World! ASH Is Global and Making a Difference